AI-generated analysis. Always verify with the original filing.
Quantum BioPharma Ltd. reported its audited financial and operational results for the fourth quarter and year ended December 31, 2025, highlighting a strong cash position, reduced operating expenses, and progress in its multiple sclerosis drug candidate and unbuzzd™ product. The company maintains sufficient working capital for operations beyond January 2028 and reported a reduction in trade payables by approximately 50%.
Event Type
Disclosure
Voluntary
Variant
6-K
Current Report on Form 6-K
| Metric | Value | Basis |
|---|---|---|
| Operating Expenses | $15.30 | |
| External Research and Development Fees | $2.80 | |
| General and Administrative Expenses | $9.00 |
Terry Lynch
Effective: 2026-03-27
constraints on his ability to dedicate an adequate amount of time to Quantum